icone plus
Contact Abonnez-vous aux actualités
Reason for request
Extension of indication
Clinical Benefit
Clinical Added Value
no clinical added value
EYLEA does not provide any improvement in actual benefit (level V, non-existent) compared with LUCENTIS for adults in the treatment of visual impairment due to macular oedema secondary to central retinal vein occlusion (CRVO).
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
vrJ8zb3PKnkmZeY3
Listen
